These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 37152764)
1. Timing and implications for immune response to vaccine in SARS-CoV-2 breakthrough infections. Arsuffi S; Sansone E; Focà E; Storti S; Diaferia T; Bonfanti C; Terlenghi L; Caruso A; Sala E; Castelli F; De Palma G; Quiros-Roldan E iScience; 2023 May; 26(5):106716. PubMed ID: 37152764 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of antibody titer kinetics and SARS-CoV-2 infections in a large cohort of healthcare professionals ten months after administration of the BNT162b2 vaccine. Ferrari D; Ambrosi A; Di Resta C; Tomaiuolo R; Locatelli M; Banfi G J Immunol Methods; 2022 Jul; 506():113293. PubMed ID: 35660546 [TBL] [Abstract][Full Text] [Related]
3. Trends in Antibody Titers after SARS-CoV-2 Vaccination-Insights from Self-Paid Tests at a General Internal Medicine Clinic. Kusunoki H; Ekawa K; Ekawa M; Kato N; Yamasaki K; Motone M; Shimizu H Medicines (Basel); 2023 Apr; 10(4):. PubMed ID: 37103782 [No Abstract] [Full Text] [Related]
4. Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine. Ferrari D; Clementi N; Criscuolo E; Ambrosi A; Corea F; Di Resta C; Tomaiuolo R; Mancini N; Locatelli M; Plebani M; Banfi G Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835288 [TBL] [Abstract][Full Text] [Related]
5. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod. Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145 [TBL] [Abstract][Full Text] [Related]
6. Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients. Biagio P; Rosa C; Nicola SM; Fabrizio S; Amerigo P; Giulia Z; Riccardo S; Riccardo V; Paolo R; Lorenzo S; Ivan G; Federico Ii Covid Team Viruses; 2022 Sep; 14(9):. PubMed ID: 36146758 [TBL] [Abstract][Full Text] [Related]
7. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675 [TBL] [Abstract][Full Text] [Related]
8. Serum and breastmilk SARS-CoV-2 specific antibodies following BNT162b2 vaccine: prolonged protection from SARS-CoV-2 in newborns and older children. Ricciardi A; Zelini P; Cassaniti I; Avanzini MA; Colaneri M; De Silvestri A; Baldanti F; Bruno R Int J Infect Dis; 2022 Sep; 122():905-909. PubMed ID: 35803470 [TBL] [Abstract][Full Text] [Related]
9. Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study. Buonfrate D; Piubelli C; Gobbi F; Martini D; Bertoli G; Ursini T; Moro L; Ronzoni N; Angheben A; Rodari P; Cardellino C; Tamarozzi F; Tais S; Rizzi E; Degani M; Deiana M; Prato M; Silva R; Bisoffi Z Clin Microbiol Infect; 2021 Dec; 27(12):1845-1850. PubMed ID: 34329793 [TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177 [TBL] [Abstract][Full Text] [Related]
11. Long-term observation of antibody titers against SARS-CoV-2 following vaccination. Sugiyama K; Suzuki C; Aoyama M; Toyota N; Nakagawa N; Shozu M; Nakai K; Iwano K Public Health Pract (Oxf); 2022 Dec; 4():100297. PubMed ID: 35847239 [TBL] [Abstract][Full Text] [Related]
13. Antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines in healthcare workers at health promotion centers: A prospective observational study. Nah EH; Cho S; Park H; Kim S; Noh D; Kwon E; Cho HI J Med Virol; 2022 Oct; 94(10):4719-4726. PubMed ID: 35655438 [TBL] [Abstract][Full Text] [Related]
14. Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers. Oliveira-Silva J; Reis T; Lopes C; Batista-Silva R; Ribeiro R; Marques G; Pacheco V; Rodrigues T; Afonso A; Pinheiro V; Araújo L; Rodrigues F; Antunes I Vaccine; 2022 Jan; 40(4):650-655. PubMed ID: 34952755 [TBL] [Abstract][Full Text] [Related]
15. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study. Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD; Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524 [TBL] [Abstract][Full Text] [Related]
16. Assessment of Seroconversion after SARS-CoV-2 Vaccination in Patients with Lung Cancer. Trontzas IP; Vathiotis I; Economidou C; Petridou I; Gomatou G; Grammoustianou M; Tsamis I; Syrigos N; Anagnostakis M; Fyta E; Sakka V; Poulakou G; Kotteas EA; Syrigou E Vaccines (Basel); 2022 Apr; 10(4):. PubMed ID: 35455367 [TBL] [Abstract][Full Text] [Related]
17. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy). Isgrò MA; Trillò G; Russo L; Tornesello AL; Buonaguro L; Tornesello ML; Miscio L; Normanno N; Bianchi AAM; Buonaguro FM; Cavalcanti E; Infect Agent Cancer; 2022 Jul; 17(1):40. PubMed ID: 35902961 [TBL] [Abstract][Full Text] [Related]
18. Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic. Brehm TT; Thompson M; Ullrich F; Schwinge D; Addo MM; Spier A; Knobloch JK; Aepfelbacher M; Lohse AW; Lütgehetmann M; Schulze Zur Wiesch J Int J Hyg Environ Health; 2021 Sep; 238():113851. PubMed ID: 34601375 [TBL] [Abstract][Full Text] [Related]
19. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study]. Özgür D; Tütüncü EE Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958 [TBL] [Abstract][Full Text] [Related]
20. Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered. López-Cortés LF; Saborido-Alconchel A; Trujillo-Rodríguez M; Serna-Gallego A; Llaves-Flores S; Muñoz-Muela E; Pérez-Santos MJ; Lozano C; Mejias-Trueba M; Roca C; Espinosa N; Gutiérrez-Valencia A Front Immunol; 2023; 14():1129753. PubMed ID: 37006309 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]